@article{ATM30762,
author = {Yu Huang and Ying Wang and Dandan Hu and Lingjuan Chen and Ruiguang Zhang and Shishi Cheng and Gang Wu and Xiaorong Dong},
title = {The influence of pemetrexed-based continuous maintenance therapy on survival of locally advanced and metastatic lung adenocarcinoma},
journal = {Annals of Translational Medicine},
volume = {7},
number = {20},
year = {2019},
keywords = {},
abstract = {Background: Patients may receive delayed maintenance therapy (stopping interval over 21 days) due to multi factors in the real-life setting. This retrospective study aims to collect data of pemetrexed-based continuous maintenance therapy, evaluate the impact of prolonged interval periods on clinical outcomes.
Methods: A total of 168 previously untreated stage IIIB or IV lung adenocarcinoma patients received induction chemotherapy with pemetrexed-platinum (PP) with or without antiangiogenesis inhibitors (bevacizumab or rh-endostatin) every 3 weeks for 4–6 cycles. Among them, 112 patients who did not show progression after induction chemotherapy completion were enrolled.
Results: Seventy of the 112 patients received continuous maintenance therapy with pemetrexed with or without antiangiogenesis inhibitors until disease progression; 42 patients did not receive continuous maintenance therapy. Multivariate analysis revealed that only lack of maintenance therapy was independently associated with shorter progression-free survival (PFS) [HR, 4.516 (2.332–8.744), P},
issn = {2305-5847}, url = {https://atm.amegroups.org/article/view/30762}
}